Invuity Sees A Clear Path In Minimally Invasive Surgery

Invuity Inc. is bringing a bright new look to the surgical field with a new type of illumination that is giving surgeons the opportunity to see inside the human body better than ever before. The company’s Eigr waveguide system directs standard light through a maze of advanced optical polymer structures that reflect and direct the light so it shines uniformly across – as one surgeon describes it – a “deep, dark incision.” Surgeons say the additional light enables them to do surgeries more quickly and effectively, and Invuity says someday its light might be capable of doing much, much more.

A primary objective of companies in the medical device field is to enable larger procedures to be done through smaller incisions. In some cases, surgeons and interventionalists can track their progress on a CT scan or through the camera of an endoscope. But those less-invasive procedures that don’t allow for that level of visualization have largely been lit by the same technology employed for decades – a ceiling light or a lamp affixed to the forehead of the surgeon. With this ambient and indirect light, surgeons are trying to perform delicate surgeries down “deep, dark holes” that will only get deeper and darker as new procedures are developed to spare patients from suffering unsightly scars or enduring unintended side effects. Performing minimally invasive surgery this way is like looking for an item under a couch using only the floor lamp behind you as illumination.

While venture capitalists and entrepreneurs spend nearly all of their time, money and efforts on creating the tools to make...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.